2004
DOI: 10.1093/abbs/36.12.798
|View full text |Cite
|
Sign up to set email alerts
|

Purification and Characterization of Jararassin-I, A Thrombin-like Enzyme from <italic>Bothrops jararaca</italic> Snake Venom

Abstract: A thrombin-like serine protease, jararassin-I, was isolated from the venom of Bothrops jararaca. The protein was obtained in high yield and purity by a single chromatographic step using the affinity resin Benzamidine-Sepharose CL-6B. SDS-PAGE and dynamic light scattering analyses indicated that the molecular mass of the enzyme was about 30 kD. The enzyme possessed fibrinogenolytic and coagulant activities. The jararassin-I degraded the Bb chain of fibrinogen while the Aa chain and g chain were unchanged. Prote… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
12
0
5

Year Published

2006
2006
2014
2014

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 25 publications
(17 citation statements)
references
References 20 publications
0
12
0
5
Order By: Relevance
“…), BpirSP-39 presented a higher coagulant potential. Other purified serine proteases such as PA-BJ and Jararassin-I from Bothrops jararaca venom show considerably reduced coagulant activity, with MCDs of 5 of 10  μ g, respectively [55, 56]. …”
Section: Discussionmentioning
confidence: 99%
“…), BpirSP-39 presented a higher coagulant potential. Other purified serine proteases such as PA-BJ and Jararassin-I from Bothrops jararaca venom show considerably reduced coagulant activity, with MCDs of 5 of 10  μ g, respectively [55, 56]. …”
Section: Discussionmentioning
confidence: 99%
“…In addition, C. durissus terrificus and Lachesis sp. venoms could also clot human fibrinogen, with no action upon B. jararaca fibrinogen [31]. …”
Section: Introductionmentioning
confidence: 99%
“…Chemical treatments for inhibition of specific enzymatic activities of L. obliqua venom Samples of Lobe (0.3 mg/ml) or thrombin (0.2 mg/ml) were added to well plates containing: (a) phenylmethanesulfonyl fluoride (PMSF) and (b) D-Phe-ProArg-chloromethylketone (PPACK) for serine proteases inhibition [20]; (c) trans-epoxysuccinyl-L-leucylamido (4-guanidino)-butane (E-64) for cysteine proteases inhibition [21]; (d) p-bromophenacyl bromide (p-BPB) for phospholipases A 2 inhibition [22] or (e) ethylene glycolbis(aminoethyl ether)-N,N,N 0 ,N 0 -tetraacetic acid (EGTA) for inhibition of metal-dependent proteases [21]. Samples were incubated for 2 h at 37°C, followed by overnight dialysis against 20 mM Tris.HCl, pH 7.4.…”
Section: Platelet Adhesion Assaymentioning
confidence: 99%